Effect of Immune Activation on the Dynamics of Human Immunodeficiency Virus Replication and on the Distribution of Viral Quasispecies

ABSTRACT Virus replication in a human immunodeficiency virus (HIV)-infected individual, as determined by the steady-state level of plasma viremia, reflects a complex balance of viral and host factors. We have previously demonstrated that immunization of HIV-infected individuals with the common recall antigen, tetanus toxoid, disrupts this steady state, resulting in transient bursts of plasma viremia after immunization. The present study defines the viral genetic basis for the transient bursts in viremia after immune activation. Tetanus immunization was associated with dramatic and generally reversible shifts in the composition of plasma viral quasispecies. The viral bursts in most cases reflected a nonspecific increase in viral replication secondary to an expanded pool of susceptible CD4+ T cells. An exception to this was in a patient who harbored viruses of differing tropisms (syncytium inducing and non-syncytium inducing [NSI]). In this situation, immunization appeared to select for the replication of NSI viruses. In one of three patients, the data suggested that immune activation resulted in the appearance in plasma of virus induced from latently infected cells. These findings illustrate certain mechanisms whereby antigenic stimulation may influence the dynamics of HIV replication, including the relative expression of different viral variants.

[1]  E. G. Shpaer,et al.  Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. , 1993, Science.

[2]  P. Simmonds,et al.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis , 1991, Journal of virology.

[3]  C. Broder,et al.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.

[4]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[5]  P. Pileri,et al.  Antigen-independent activation of naive and memory resting T cells by a cytokine combination , 1994, The Journal of experimental medicine.

[6]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[7]  Anthony S. Fauci,et al.  Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.

[8]  C. Kuiken,et al.  Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population , 1995, Journal of virology.

[9]  S. Swindells,et al.  Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[10]  T. Elbeik,et al.  Activation of virus replication after vaccination of HIV-1-infected individuals , 1995, The Journal of experimental medicine.

[11]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[12]  M. Ostrowski,et al.  Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. , 1998, Journal of immunology.

[13]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[14]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[15]  C. Mackay,et al.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Albert,et al.  REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.

[18]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[19]  M. Ascher,et al.  AIDS as immune system activation. II. The panergic imnesia hypothesis. , 1990, Journal of acquired immune deficiency syndromes.

[20]  M P Dempsey,et al.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. , 1991, Science.

[21]  W. Allan,et al.  Activation of cytokine genes in T cells during primary and secondary murine influenza pneumonia , 1993, The Journal of experimental medicine.

[22]  Martin A. Nowak,et al.  Causes of HIV diversity , 1995, Nature.

[23]  Z. Grossman,et al.  Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[25]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[26]  D. Weissman,et al.  Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. , 1996, Journal of immunology.

[27]  W. O'brien,et al.  Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. , 1995, Blood.

[28]  É. Oksenhendler,et al.  HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes , 1994, Cell.

[29]  E. Holmes,et al.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop , 1994, Journal of virology.

[30]  H. Bremermann,et al.  Aids as Immune System Activation , 1995 .

[31]  M. Kimura.  The Neutral Theory of Molecular Evolution: Introduction , 1983 .

[32]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[33]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[34]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[35]  Lawrence Corey,et al.  Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.

[36]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[37]  B. Chesebro,et al.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism , 1992, Journal of virology.

[38]  J. Adachi,et al.  MOLPHY version 2.3 : programs for molecular phylogenetics based on maximum likelihood , 1996 .

[39]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[40]  D. Ho.  HIV-1 viraemia and influenza , 1992, The Lancet.

[41]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[42]  P. Kvale,et al.  A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[43]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[44]  N. Letvin,et al.  Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination , 1998, Nature Medicine.

[45]  Characterization,et al.  Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. , 1994, AIDS research and human retroviruses.

[46]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[47]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[48]  M. Nei,et al.  Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. , 1986, Molecular biology and evolution.

[49]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[50]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[51]  A. Fauci,et al.  Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.

[52]  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. , 1991, Disease markers.

[53]  R. Doms,et al.  Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.

[54]  A. Rodrigo,et al.  Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay. , 1995, PCR methods and applications.

[55]  T. Jukes,et al.  The neutral theory of molecular evolution. , 2000, Genetics.

[56]  C H Fox,et al.  Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. , 1996, The New England journal of medicine.